ZNF14 Inhibitors

Chemical inhibitors of ZNF14 disrupt its ability to bind DNA by various means, each targeting the interaction between the protein and the DNA in unique ways. Chloroquine intercalates into DNA, which can obstruct the DNA-binding domain of ZNF14, preventing the protein from attaching to its target DNA sequences. Similarly, Etoposide and Mitoxantrone both target DNA topology; Etoposide by stabilizing the DNA-topoisomerase II complex and Mitoxantrone by intercalating into DNA. These actions result in altered DNA structures, which can reduce ZNF14's DNA binding affinity. Mithramycin A and Actinomycin D interfere with DNA binding as well; Mithramycin A by binding to G-C rich sequences and Actinomycin D by binding at the transcription initiation complex, both of which can block ZNF14's access to its binding sites.

Further inhibitory mechanisms are employed by Netropsin and Distamycin A, which bind to the minor groove of DNA, particularly at AT-rich sequences, creating a physical barrier to ZNF14's access to these regions. Pentamidine operates similarly, by binding to the minor groove and likely causing a steric hindrance to the interaction of ZNF14 with DNA. Trabectedin bends DNA upon binding, which can disrupt the recognition of DNA by ZNF14, while Bizelesin and Tallimustine form covalent bonds with DNA, resulting in cross-links and alkylation, respectively, that can impede ZNF14's ability to effectively engage with its target sequences. Lastly, Plicamycin, by intercalating between guanine-cytosine base pairs, can inhibit the interaction of ZNF14 with its DNA recognition sequences, reducing the protein's functional activity within the cell.